{"type":"rich","version":"1.0","provider_name":"Transistor","provider_url":"https://transistor.fm","author_name":"In the Interim...","title":"The Legend of I-SPY 2 - Part A","html":"<iframe width=\"100%\" height=\"180\" frameborder=\"no\" scrolling=\"no\" seamless src=\"https://share.transistor.fm/e/0b0304b0\"></iframe>","width":"100%","height":180,"duration":2409,"description":"In Episode 20 of Berry’s \"In the Interim...\" Podcast, The Legend of I-SPY 2 - Part A, Dr. Don Berry and Dr. Scott Berry discuss the origins and design of the I-SPY trials. Their conversation explains the inefficiency of traditional adjuvant breast cancer trials and details the shift to the neoadjuvant approach, where tumor response can be observed prior to surgery. I-SPY 1 served as a proof-of-concept using MRI for probabilistic prediction of pathologic complete response (pCR). I-SPY 2 represents a major advancement in clinical trial science, introducing a multi-arm bandit methodology, integration of biomarker-driven subtypes and signatures, and a structured funding model that transitioned from philanthropy to “pay to play” industry support.","thumbnail_url":"https://img.transistorcdn.com/toFATB0JXvqQXRqzUqrK1EWCJCLOA_Qvjkb5ml3q-s8/rs:fill:0:0:1/w:400/h:400/q:60/mb:500000/aHR0cHM6Ly9pbWct/dXBsb2FkLXByb2R1/Y3Rpb24udHJhbnNp/c3Rvci5mbS9jM2M0/ZDE2YzA1N2FhNjkx/NDk1NDczNjYzM2E5/NjlmYS5wbmc.webp","thumbnail_width":300,"thumbnail_height":300}